Simultaneous carcinoembryonic antigen (CEA), carcinoma antigen 19-9 (CA 19-9) and 125 (CA-125) measurement in patients with gastric cancer (stage I...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter F. Lumachi
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors F. Lumachi1, G. Chiara2, R. Tozzoli3, G. Lo Re4, S. Basso2
  • 1Department of Surgery, Oncology & Gastroenterology, University of Padua, School of Medicine, Padova, Italy, /
  • 2Chirurgia 1, S. Maria degli Angeli Hospital, Pordenone, Italy, /
  • 3Department of Clinical Pathology, S. Maria degli Angeli Hospital, Pordenone, Italy, /
  • 4Department of Oncology, General Hospital "S. Maria degli Angeli", Pordenone, Italy, /

Abstract

Gastric cancer (GC) is a rare malignancy in Western countries, accounting approximately for 1.5% of all cancers in the USA. However, worldwide, the expected new cases in 2015 were 630,000 and 320,000 among men and women, respectively, with more than 700,000 deaths. Also in the European Union the incidence of GC has been progressively reduced during the last 20 years. The use of serum tumor markers is common in patients with cancer, including GC. Unfortunately, none have shown a high sensitivity to be routinely considered in the screening of patients. We evaluated the usefulness of combined carcinoembryonic antigen (CEA), carcinoma antigen 19-9 (CA 19-9) and 125 (CA-125) measurement in early diagnosis of GC.